ARCHIMED Consumer Health announces partnership with Organika, a leading Canadian health and wellness brand.

Organika Health Products is a nutraceutical specialist, centered on supplementation, the fastest growing segment of the global Vitamins, Minerals and Supplements market.

 

The Consumer Health team of ARCHIMED, a global private equity healthcare specialist, today announces its investment in Organika, the leader in the Canadian nutraceutical market – food-based substances formulated for their medical or health benefits. The partnership will accelerate the next phase of growth for the Company.

Founded in 1990 and headquartered in Vancouver, B.C., Organika is a recognized expert in the supplementation subsector, where specific nutrients and plant compounds are isolated and delivered in pharma-style formats such as capsules, tablets, softgels, powders and liquids.

Over the years, Organika has developed a global portfolio of products spanning hydration, collagen, protein, immunity, bone and joint health, gut health, sleep and relaxation, energy, and stress relief – backed by strong brand equity with healthcare practitioners, a scaled distribution network, and an innovation engine with a proven record of bringing high-quality products to market.

“Partnering with ARCHIMED marks an exciting new chapter for Organika,” said Aaron Chin, who will continue to lead the company as CEO. “Our ambition is to set a new standard for trusted, science-backed wellness—first in Canada and increasingly around the world. We chose ARCHIMED because they share our long-term vision and bring deep healthcare expertise, global capabilities and a genuine commitment to building alongside us. Together, we will invest more boldly in science, innovation, technology and international expansion, while preserving the entrepreneurial spirit, uncompromising quality and trusted relationships that have made Organika who we are. This partnership brings together the best of both organizations and gives us the opportunity to build something truly exceptional.”

The Vitamins, Minerals, and Supplements market has long been a priority for the ARCHIMED Consumer Health team, which identified Organika as a category leader through MedSeg, ARCHIMED’s proprietary sector analysis tool covering 500+ sub-segments of the health industry. The deal was sourced directly through a team member’s relationship with the founding family.

ARCHIMED is investing in Organika through its MED III and MED IV funds. MED III closed on €650 million in 2021 and MED IV – three-times oversubscribed – closed on €1.5 billion in September of this year. Organika is MED IV’s first investment. All of ARCHIMED’s deployed buyout funds from the 2019, 2021, and 2022 vintages are top-quartile performers for their respective vintage years (Preqin 2026).

Past performance is not a guarantee of future results. Capital at risk. For professional investors only.